drugset / Trial / NCT00177554

Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma

NCT00177554

Phase 2 Completed 60 enrolled University of Pittsburgh Biogen · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma

Timeline

Start
2003-11
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified
Subject Doxorubicin Other / unclassified
Subject Prednisone Other / unclassified
Subject Rituximab Monoclonal antibody
Subject Vincristine Small molecule
Subject ibritumomab tiuxetan Monoclonal antibody

Indications